Exelixis Inc Sales Discounts, Returns and Allowances, Goods (Deprecated 2018-01-31)
Exelixis Inc (EXEL) reported Sales Discounts, Returns and Allowances, Goods (Deprecated 2018-01-31) of $26.81 million for the 3-month period ending 2018-06-29, per its 10-Q filed 2018-08-01.
Discontinued › Notes
us-gaap:SalesDiscountsReturnsAndAllowancesGoods · last filed 2018-08-01
- Exelixis Inc sales discounts, returns and allowances, goods (deprecated 2018-01-31) for the quarter ending 2018-06-29 was $26.81M, a 118.79% increase year-over-year.
- Exelixis Inc sales discounts, returns and allowances, goods (deprecated 2018-01-31) for the quarter ending 2018-03-30 was $25.16M, a 177.08% increase year-over-year.
- Exelixis Inc sales discounts, returns and allowances, goods (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $12.25M.
- Exelixis Inc sales discounts, returns and allowances, goods (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $9.08M.
| Period end | Sales Discounts, Returns and Allowances, Goods (Deprecated 2018-01-31) 3 month | Sales Discounts, Returns and Allowances, Goods (Deprecated 2018-01-31) 6 month | Sales Discounts, Returns and Allowances, Goods (Deprecated 2018-01-31) 9 month |
|---|---|---|---|
| 2018-06-29 | $26.81M 10-Q · filed 2018-08-01 | $51.97M 10-Q · filed 2018-08-01 | |
| 2018-03-30 | $25.16M 10-Q · filed 2018-05-02 | ||
| 2017-06-30 | $12.25M 10-Q · filed 2018-08-01 | $21.34M 10-Q · filed 2018-08-01 | |
| 2017-03-31 | $9.08M 10-Q · filed 2018-05-02 | ||
| 2014-09-30 | $1.80M 10-Q · filed 2015-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |